Pacira BioSciences (PCRX) Receivables (2010 - 2026)

Pacira BioSciences' Receivables history runs 17 years deep, the most recent figure standing at $125.6 million for Q1 2026.

• On a quarterly basis, Receivables rose 19.94% year-over-year to $125.6 million in Q1 2026; TTM through Mar 2026 was $125.6 million, a 19.94% increase from a year earlier, with the FY2025 full-year figure at $124.1 million, up 9.5% from the prior year.
• Receivables advanced to $125.6 million in Q1 2026 per PCRX's latest filing, from $124.1 million in the prior quarter.
• Across five years, Receivables topped out at $125.6 million in Q1 2026 and bottomed at $91.1 million in Q2 2022.
• The 5-year median for Receivables is $101.6 million (2024), against an average of $104.4 million.
• Across the five-year window, Receivables jumped 87.04% in 2022 and rose 1.2% in 2023, its largest moves.
• Year by year, Receivables stood at $98.4 million in 2022, then advanced by 7.28% to $105.6 million in 2023, then increased by 7.34% to $113.3 million in 2024, then rose by 9.5% to $124.1 million in 2025, then increased by 1.26% to $125.6 million in 2026.
• Per Business Quant, the three latest PCRX Receivables figures stand at $125.6 million (Q1 2026), $124.1 million (Q4 2025), and $115.3 million (Q3 2025).